KRAS and leukemia: In addition to leukemia-driving mutations, we have identified recurrent pathogenic mutations CRLF2 p.F232C (n = 7), TYK2 p.A413T (n = 7), JAK2 p.R683G (n = 4), KRAS p.G12D (n = 4), FLT3 p.Y842C (n = 3) and PTPN11 p.D61V (n = 3), previously frequently found in pediatric ALL (Table S4 and Figure S1).